Latest & greatest articles for osteoarthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoarthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoarthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoarthritis

561. The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis

The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis Maetzel A, Krahn M, Naglie G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Maetzel A, Krahn M, Naglie G. The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Technology Report No. 23. 2002 Authors' objectives The purpose of this assessment is to evaluate the long-term cost-effectiveness of the COX2 NSAIDs celecoxib, in comparison to diclofenac and ibuprofen, and rofecoxib in comparison to naproxen

2002 Health Technology Assessment (HTA) Database.

562. S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease

S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease Hardy M, Coulter I, Morton SC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) Hardy M, Coulter I, Morton SC. S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 64. 2002 Authors' objectives This report is a comprehensive literature review and synthesis of evidence on the use of S-adenosyl-L-methionine (SAMe) for the treatment of depression, osteoarthritis, and liver disease. Authors' conclusions These data indicate that SAMe is more

2002 Health Technology Assessment (HTA) Database.

563. Hip resurfacing in patients with osteoarthritis

Hip resurfacing in patients with osteoarthritis Hip resurfacing in patients with osteoarthritis Hip resurfacing in patients with osteoarthritis Bernath V Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bernath V. Hip resurfacing in patients with osteoarthritis. Clayton, Victoria: Centre for Clinical Effectiveness (CCE) 2002: 9 Authors' objectives This aim (...) of this critical appraisal was to assess how hip resurfacing (Birmingham hip) compares with total hip replacement in improving mobility in patients who have osteoarthritis in the hip. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Arthroplasty; Osteoarthritis, Hip Language Published English Country of organisation Australia Address for correspondence Monash Institute of Health Services Research, Block E, Monash Medical Centre, Locked Bag 29, Clayton, Victoria 3168, Australia. Tel: +61 3

2002 Health Technology Assessment (HTA) Database.

564. Efficacy of balneotherapy for osteoarthritis of the knee: a systematic review

, research should aim to determine the most effective treatment to introduce at the various stages of the disease. Funding Arthritis Society (Canada); Ontario Ministry of Health; Department of Human Resources Development of Canada (Summer Student Program). Bibliographic details Brosseau L, MacLeay L, Robinson V, Casimiro L, Pelland L, Wells G, Tugwell P, McGowan J. Efficacy of balneotherapy for osteoarthritis of the knee: a systematic review. Physical Therapy Reviews 2002; 7(4): 209-222 Other (...) publications of related interest Brosseau L, Robinson V, Pelland L, Casimiro L, Milne S, Judd M et al. Efficacy of balneotherapy in rheumatoid arthritis: a meta-analysis. Phys Ther Rev 2002;7:67-87. Indexing Status Subject indexing assigned by CRD MeSH Arthritis, Rheumatoid /therapy; Balneology; Hydrotherapy; Knee Joint; Osteoarthritis /therapy; Range of Motion, Articular AccessionNumber 12005005093 Date bibliographic record published 31/05/2007 Date abstract record published 31/05/2007 Record Status

2002 DARE.

565. Pulsed signal therapy and the treatment of osteoarthritis

in the review Patients with osteoarthritis were eligible for inclusion. Participants in two of the included studies had osteoarthritis of the knee; in one study patients with osteoarthritis of the cervical spine were included; and in another, patients with cervical and lumbar spondylosis were included. One study was excluded partly because it included patients in the treatment group with different affected joints to those in the control group. Outcomes assessed in the review The inclusion criteria (...) , compared to baseline, at the end of treatment and at the 3- and 6-month follow-ups in patients with cervical or lumbar spondylosis. In the other cohort study (n=34) which had no control group, on average, the pain index decreased from 7.12 to 2.38 from baseline to the one-year follow-up in patients with osteoarthritis of the knee; pain on motion decreased from 7.15 to 1.47 for the same time period. Authors' conclusions The results strongly suggest that PST has an analgesic effect and improves joint

2002 DARE.

566. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials

) osteoarthritis index (for pain, stiffness and physical function), the American College of Rheumatology (ACR-20) responder index, and joint scores (number of painful or tender swollen joints) for rheumatoid arthritis. For tolerability, the withdrawal rates for adverse effects (at 12 weeks) were reported. For gastrointestinal safety, the incidence of ulcers detected by routine endoscopy (at 12 and 24 weeks) and the incidence of symptomatic ulcers, bleeds, perforations and obstructions (up to 24 weeks) were (...) and control (drug, dose and number randomised), duration, outcome measures for efficacy, and outcome measures used to measure upper gastrointestinal safety. Methods of synthesis How were the studies combined? Separate meta-analyses were undertaken for each comparison and outcome. The efficacy data were analysed separately for osteoarthritis and rheumatoid arthritis, but the two diseases were combined for the analysis of tolerability and safety. Dichotomous data were summarised as a relative risk (RR

2002 DARE.

567. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. (Abstract)

Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Treatment of osteoarthritis is usually limited to short-term symptom control. We assessed the effects of the specific drug glucosamine sulphate on the long-term progression of osteoarthritis joint structure changes and symptoms.We did a randomised, double-blind placebo controlled trial, in which 212 patients with knee osteoarthritis were randomly assigned 1500 mg sulphate (...) oral glucosamine or placebo once daily for 3 years. Weightbearing, anteroposterior radiographs of each knee in full extension were taken at enrolment and after 1 and 3 years. Mean joint-space width of the medial compartment of the tibiofemoral joint was assessed by digital image analysis, whereas minimum joint-space width--ie, at the narrowest point--was measured by visual inspection with a magnifying lens. Symptoms were scored by the Western Ontario and McMaster Universities (WOMAC) osteoarthritis

2001 Lancet Controlled trial quality: predicted high

568. Therapeutic ultrasound for osteoarthritis of the knee. (Abstract)

abstracted by two reviewers (VW, LB), and checked by a third reviewer (BS) using a pre-developed adapted form for the OA sub-group of the Cochrane Musculoskeletal Group. The same two reviewers, using a validated scale, assessed the methodological quality of the RCTs and CCTs independently. OA outcome measures were extracted from the publications. The pooled analysis was performed using weighted mean differences (WMDs) for joint counts, pain, global and functional assessments. A chi-square test was used (...) galvanic current or short wave diathermy for the outcomes of pain and patient-assessed improvement.Ultrasound therapy appears to have no benefit over placebo or short wave diathermy for patients with knee OA. These conclusions are limited by the poor reporting of the characteristics of the device, of the population, of the OA,and therapeutic application of the ultrasound and low methodological quality of the trials included. No conclusions can be drawn about the use of ultrasound in smaller joints

2001 Cochrane

569. Glucosamine therapy for treating osteoarthritis. (Abstract)

Glucosamine therapy for treating osteoarthritis. Osteoarthritis (OA) is the most common form of arthritis, and it is often associated with significant disability and an impaired quality of life.To review all randomized controlled trials (RCTs) evaluating the effectiveness and toxicity of glucosamine in osteoarthritis (OA).We searched MEDLINE, Embase, and Current Contents up to November 1999, and the Cochrane Controlled Trials Register. We also wrote letters to content experts, and hand searched (...) reference lists of identified RCTs and pertinent review articles.Relevant studies met the following criteria: 1) RCTs evaluating the effectiveness and safety of glucosamine in OA, 2) Both placebo based and comparative studies were eligible, 3) Both single blinded and double-blinded studies were eligible.Data abstraction was performed independently by two investigators and the results were compared for degree of agreement. Gotzsche's method and a validated tool (Jadad 1995) were used to score the quality

2001 Cochrane

570. Herbal therapy for treating osteoarthritis. (Abstract)

Herbal therapy for treating osteoarthritis. The increasing popularity of complementary and alternative medicine appears to be particularly evident amongst people with chronic disease. In the treatment of osteoarthritis, one therapy that has been identified as having potential benefit, is herbal medicine (phytotherapy).To determine the effectiveness of herbal therapies in treating osteoarthritis.Databases for mainstream and complementary medicine were searched using terms to include all forms (...) of arthritis combined with herbal medicine. We searched the following electronic databases: MEDLINE, EMBASE, CISCOM, AMED, CINAHL, Cochrane Controlled Trials Register (CCTR), Cochrane Musculoskeletal specialized register, Dissertation Abstracts, BIDS ISI and the Cochrane Complementary Medicine Fields Specialized Register. We also searched the reference lists from retrieved trials.All randomized trials of herbal interventions in osteoarthritis, compared to placebo. Studies were included according

2001 Cochrane

571. Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis

evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of rofecoxib versus nonselective non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of osteoarthritis (OA). Three daily dosages of rofecoxib could be administered, 12.5, 25 or 50 mg (the average daily dose was 24.7 mg (...) Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis Pellissier J M, Straus W L, Watson D J, Kon S X, Harper S E Record Status This is a critical abstract of an economic

2001 NHS Economic Evaluation Database.

572. Economic evaluation of aquatic exercise for persons with osteoarthritis

by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of aquatic exercise was compared with usual care for patients with osteoarthritis. Type of intervention Secondary prevention. Economic study type Cost-utility analysis. Study population The study population comprised patients with osteoarthritis. The site of the osteoarthritis, in terms of the affected joint, was not defined. The participants were eligible for inclusion if they met (...) the following criteria: there was a clinically confirmed diagnosis of osteoarthritis from a physician; they were aged 55 to 75 years; they were not currently exercising, defined as engaging in an average of less than 60 minutes exercise per week during the last month; they had permission from their primary physician to participate in the aquatic class; they were not currently enrolled in another medical study; they were not scheduled for joint replacement during the study; they were living in an area where

2001 NHS Economic Evaluation Database.

573. Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in France, Italy and Spain

for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of two drug therapies, nimesulide and diclofenac, for the treatment of osteoarthritis (OA). Both drugs are nonsteroidal anti-inflammatory drugs (NSAIDs), which although beneficial in reducing pain and inflammation, may result in potentially serious consequences in terms (...) Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in France, Italy and Spain Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in France, Italy and Spain Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in France, Italy and Spain Tarricone R, Martelli E, Parazzini F, Darba J, Le Pen C, Rovira J Record Status This is a critical abstract of an economic evaluation that meets the criteria

2001 NHS Economic Evaluation Database.

574. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective

A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health intervention examined in the study was rofecoxib (24.7 mg daily) for the treatment of patients with osteoarthritis (OA). Type of intervention Treatment. Economic study type (...) Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective Marshall J K, Pellissier J M, Attard C L, Kong S X, Marentette M

2001 NHS Economic Evaluation Database.

575. Health economic comparisons of rofecoxib versus conventional nonsteroidal antiinflammatory drugs for osteoarthritis in the United Kingdom

Health economic comparisons of rofecoxib versus conventional nonsteroidal antiinflammatory drugs for osteoarthritis in the United Kingdom Health economic comparisons of rofecoxib versus conventional nonsteroidal antiinflammatory drugs for osteoarthritis in the United Kingdom Health economic comparisons of rofecoxib versus conventional nonsteroidal antiinflammatory drugs for osteoarthritis in the United Kingdom Moore R A, Phillips C J, Pellissier J M, Kong S X Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technology under investigation was rofecoxib, a new drug for the treatment of patients suffering from osteoarthritis. It is a selective COX-2 inhibitor and represents one of the two drugs in the "Coxibs

2001 NHS Economic Evaluation Database.

576. Safety profile of nonprescription ibuprofen in the elderly osteoarthritis patient: a meta-analysis

Safety profile of nonprescription ibuprofen in the elderly osteoarthritis patient: a meta-analysis Safety profile of nonprescription ibuprofen in the elderly osteoarthritis patient: a meta-analysis Safety profile of nonprescription ibuprofen in the elderly osteoarthritis patient: a meta-analysis Ashraf E, Cooper S, Kellstein D, Jayawardena S Authors' objectives To assess the incidence of adverse experiences among elderly people taking multiple doses of non-prescription ibuprofen (...) for osteoarthritis pain, compared with placebo. Searching MEDLINE, EMBASE, BIOSIS Previews, International Pharmaceutical Abstracts, SciSearch, TOXLINE, CA SEARCH: Chemical Abstracts were searched. The dates and search terms were not reported. A textbook published in 1999 was also consulted. Study selection Study designs of evaluations included in the review Randomised trials (RCTs) that were double-blind and had a parallel-group design (not crossover) were eligible for inclusion. Specific interventions included

2001 DARE.

577. Use of Hyaluronan in osteoarthritis of the knee (Sodium hyaluronate for intra-articular injection)

Use of Hyaluronan in osteoarthritis of the knee (Sodium hyaluronate for intra-articular injection) Use of Hyaluronan in osteoarthritis of the knee (Sodium hyaluronate for intra-articular injection) Use of Hyaluronan in osteoarthritis of the knee (Sodium hyaluronate for intra-articular injection) Medical Technology Unit - Swiss Federal Office of Public Health Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Medical Technology Unit - Swiss Federal Office of Public Health. Use of Hyaluronan in osteoarthritis of the knee (Sodium hyaluronate for intra-articular injection) Medical Technology Unit - Swiss Federal Office of Public Health (MTU-SFOPH). 2001 Authors' objectives The aim of this report was to assess the statistical significance for the efficacy, tolerability and safety of Ostenil compared to Synvisc for the treatment

2001 Health Technology Assessment (HTA) Database.

578. Hip resurfacing in younger people with osteoarthritis

Hip resurfacing in younger people with osteoarthritis Hip resurfacing in younger people with osteoarthritis Hip resurfacing in younger people with osteoarthritis Bisset A F Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bisset A F. Hip resurfacing in younger people with osteoarthritis. London: Bazian Ltd (Editors), Wessex Institute for Health Research (...) and Development, University of Southampton 2001: 7 Authors' objectives This study aims to assess the effects of hip resurfacing for osteoarthritis in people under 65, compared with total hip replacement (THR). Authors' conclusions No evidence-based recommendations may be made from the research identified by our search. We found insufficient evidence about comparative efficacy of resurfacing versus replacement for this age group, although it could be argued that benefits and harms of THR are currently better

2001 Health Technology Assessment (HTA) Database.

579. Pulsed signal therapy and the treatment of osteoarthritis

Modes d'Intervention en Sante. Pulsed signal therapy and the treatment of osteoarthritis. Montreal: Agence d'evaluation des technologies et des modes d'intervention en sante (AETMIS). AETMIS 01-2 RE. 2001 Authors' objectives The purpose of this report is to assess the efficacy of pulsed signal therapy (PST) in relieving pain and improving joint function in osteoarthritis. Authors' conclusions Osteoarthritis is a disease with a high prevalence, especially among the elderly. Having a noninvasive (...) conclusions can be drawn from the available scientific data, the latter strongly point to an analgesic effect and improved joint function in osteoarthritis. Furthermore, this technology cannot be considered purely experimental, since it is already being used by physiotherapy clinics, physicians in private practice and private individuals in Quebec and elsewhere in the world and since the user professionals consulted believe that pulsed electromagnetic field therapy may have a role to play

2001 Health Technology Assessment (HTA) Database.

580. The Oxford unicompartmental knee replacement for osteoarthritis

The Oxford unicompartmental knee replacement for osteoarthritis The Oxford unicompartmental knee replacement for osteoarthritis The Oxford unicompartmental knee replacement for osteoarthritis Brown A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Brown A. The Oxford unicompartmental knee replacement for osteoarthritis. Ottawa: Canadian (...) Coordinating Office for Health Technology Assessment/Office Canadien de Coordination de l'Evaluation des Technologies de la Sante (CCOHTA) 2001: 4 Authors' objectives To summarise the available evidence on the use of the Oxford unicompartmental knee replacement for osteoarthritis. Authors' conclusions The Oxford unicompartmental knee replacement is a reliable treatment for medial knee compartment osteoarthritis, provided patients with the correct indications are chosen and the appropriate surgical

2001 Health Technology Assessment (HTA) Database.